János Szücs
Semmelweis University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by János Szücs.
Calcified Tissue International | 1992
János Szücs; Csaba Horváth; Éva Kollin; Miklós Szathmári; I. Holló
SummaryForty-five postmenopausal osteoporotic women with at least one osteoporotic vertebral crush fracture were randomized into three treatment groups. Each patient was on calcitonin, 50 U, on alternate days for 2 weeks monthly (350 U/month), and 500 mg/day oral calcium supplementation. In group II, this therapy was supplemented with phosphate (750 mg/day), and in group III, norandrostenolone decanoate (50 mg/month) was added to the calcitonin + calcium therapy. Bone mineral content, by single photon absorptiometry, of the radius midshaft and distal site (3 cm), as well as the lumbar and metacarpal radiomorphometrical indices were estimated semiannually. The therapeutic trial lasted 36 months except in the phosphate supplementation group, where, due to unfavorable results, treatment was discontinued after 24 months. Calcitonin practically prevented further bone loss for 24 months even in this relatively small and intermittent dosage. Phosphate supplementation was without benefit; however, according to the majority of the examined parameters, combination of calcitonin with the anabolic steroid norandrostenolone decanoate extended efficacy up to 36 months. This latter combination seems to be a promising, relatively inexpensive therapeutic regimen in the treatment of established postmenopausal osteoporosis.
Calcified Tissue International | 1986
János Zséli; P. Bösze; Ferenc Szalay; János Szücs; Csaba Horváth; Éva Kollin; Miklós Szathmári; János F. László; I. Holló
SummaryOsteoporosis in one of the most common complications of streak gonad syndrome (SGS), however, its pathogenesis is still unclear. To test whether SGS is associated with calcitonin (CT) deficiency, 11 affected individuals and 8 age-matched healthy women were studied. Calcium, 3.6 mg/kg b.w. as a 10% solution of calcium chloride, was given intravenously for 3 minutes. Serum levels of CT and calcium were measured before and at 5, 30, 60, and 120 minutes after the injection. There was a statistically significant rise in serum calcium levels both in the control subjects and patients with SGS, with significantly lower levels prior to and at 30, 60, and 120 minutes following calcium load in the control group. The CT rise following calcium load was also significant at 5, 30, and 60 minutes in the controls and at 5 and 30 minutes in patients with SGS, with a significantly lower baseline and 30, 60, and 120 minutes levels in the latter group. Maximum levels of calcium and CT occurred 5 minutes after the calcium load and were statistically indistinguishable. There were no significant differences in either the calcium or the CT incremental changes between the two groups. These findings are consistent with decreased basal (and 30–120 minute) CT levels in SGS and suggest that CT deficiency may be involved in the development of osteoporosis in patients with SGS. The possible causal relationship of estrogen deficiency to the reduced CT levels in SGS is discussed.
The Lancet | 1976
I. Holló; Ferenc Szalay; János Szücs; M. Boross
The Lancet | 1976
I. Holló; Ferenc Szalay; János Szücs; M. Boross
Anticancer Research | 1998
Jozsef Bocsi; Ferenc Perner; János Szücs; Edit Gláz; László Kopper
The Lancet | 1971
I. Holló; Mária Boross; János Szücs
The Lancet | 1982
János Zséli; Csaba Horváth; János Szücs; I. Holló
Experimental and Clinical Endocrinology & Diabetes | 2005
Emoke Csupor; Edit Tóth; Szilvia Mészáros; Viktória Ferencz; János Szücs; Peter L. Lakatos; J. Horányi; F. Perner; Csaba Horváth
The Lancet | 1974
János Szücs
Lege Artis Medicinae | 2003
Emoke Csupor; János Szücs; Szilvia Mészáros; Peter L. Lakatos; Edit Tóth; Csaba Horváth